Anki Malmborg Hager has had a hand in the development of many of Lund’s most exciting life science companies and has been CEO of four of them. She was also involved at an early stage with Immunovia and Alligator Bioscience, where she subsequently served as Vice President.
Later, she ran the biotech company Senzagen from a business idea based on an innovation – animal-free testing of suspected allergenic chemicals – to commercial phase, and launched the company on Nasdaq First North in 2017. When she left Senzagen two years later, the company had grown from having no cash on hand to being worth almost SEK 500 million on the stock market. Most recently, she served as CEO of PainDrainer, a company that she ran from startup until the present, when it is ready to launch an AI-based pain management product on the market.